Gustave Roussy Institute and Merus Partner for Novel Cancer Therapeutics Development

The Gustave Roussy Institute and Merus collaborate to jointly develop bispecific antibodies for oncology applications.

J&J Reports 66% Overall Efficacy for One-Dose COVID-19 Vaccine

J&J acknowledged that the efficacy percentages varied depending where the vaccine was administered, with a low of 57% in South Africa, where a variant strain of SARS-CoV-2 from the from the B.1.351 lineage accounted nearly all cases 28 days post-vaccination. Percentages stood at 66% in Latin America and 72% in the U.S.

Eleven Increases Series A Fundraising to $45M for Protein Therapeutics Pipeline

Start of Phase I trials with topical IL-1 antagonist against dry eye syndrome is expected this year.

Sanofi Obtains Access to MAB Discovery’s Antibody Technology

MAB Discovery has added Sanofi to its list of partners through a monoclonal antibody research and license agreement announced today.

ProteoTech, GSK Come Together for Parkinson Drug R&D

Firms aim to bolster ProteoTech's alpha-synuclein program.

AstraZeneca, Daiichi Sankyo Launch Potentially $6.9B+ Collaboration to Develop Cancer ADC

AstraZeneca has agreed to pay potentially more than $6.9 billion to co-develop Daiichi Sankyo’s Trastuzumab deruxtecan—just months before the first application to market the...

Top 15 Immuno-Oncology Collaborations

The top 15 immuno-oncology collaborations' total value of all 15 ranked collaborations is approximately $30 billion.

COVID-19 Vaccine Progress in Pittsburgh

Scientists at the University of Pittsburgh School of Medicine announced a positive step forward in the development of a potential vaccine against SARS-CoV-2. The vaccine, which can be delivered through a fingertip-sized patch that does not require refrigeration, produces SARS-CoV-2 specific antibodies in mice at quantities thought to be sufficient for neutralizing the virus. The authors hope to start a Phase I human clinical trial within a few months.

Celerion, Ricerca Launch Dedicated Biosimilars Development Service Offerings

Alliance will provide clients with full suite of services to bring biosilimilars to market.

TRIB1 Inhibition in Macrophages Could be New Cardiovascular Disease Therapy Target

Researchers from the University of Sheffield say they have identified a new potential treatment pathway for cardiovascular disease.